Complete-case analysis revealed that hazard ratios for all-cause death (HR 0.70; 95% CI, 0.47–1.04) and stroke (HR 0.66; 95% CI, 0.29–1.50) were numerically lower among patients receiving SGLT2 inhibitors, although these reductions did not reach statistical significance.
1
—
—